
Synthetic Biologics, Inc. – AMEX:SYN
Synthetic Biologics stock price today
Synthetic Biologics stock price monthly change
Synthetic Biologics stock price quarterly change
Synthetic Biologics stock price yearly change
Synthetic Biologics key metrics
Market Cap | 16.16M |
Enterprise value | N/A |
P/E | -8.5 |
EV/Sales | N/A |
EV/EBITDA | 1.94 |
Price/Sales | N/A |
Price/Book | 0.26 |
PEG ratio | -0.13 |
EPS | -1.17 |
Revenue | N/A |
EBITDA | -21.90M |
Income | -18.01M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeSynthetic Biologics stock price history
Synthetic Biologics stock forecast
Synthetic Biologics financial statements
Dec 2022 | 0 | -5.15M | |
---|---|---|---|
Mar 2023 | 0 | -4.47M | |
Jun 2023 | 0 | -5.08M | |
Sep 2023 | 0 | -3.30M |
2022-05-16 | -0.3 | -0.3 |
---|---|---|
2022-08-11 | -0.35 | -0.31 |
Payout ratio | 0% |
---|
2018 | 3346.83% |
---|---|
2019 | 63.01% |
2020 | 189.53% |
2021 | 45.1% |
2022 |
Dec 2022 | 71861000 | 17.29M | 24.07% |
---|---|---|---|
Mar 2023 | 67886000 | 17.3M | 25.48% |
Jun 2023 | 65449000 | 17.69M | 27.04% |
Sep 2023 | 61545000 | 17.66M | 28.7% |
Mar 2022 | -4.90M | -4.28M | -1.37M |
---|---|---|---|
Jun 2022 | -4.35M | -14K | -1.37M |
Dec 2022 | -5.01M | -102K | 822K |
Mar 2023 | -5.61M | -8K | -55K |
Synthetic Biologics alternative data
Aug 2023 | 16 |
---|---|
Sep 2023 | 16 |
Oct 2023 | 16 |
Nov 2023 | 16 |
Dec 2023 | 16 |
Jan 2024 | 16 |
Feb 2024 | 16 |
Mar 2024 | 16 |
Apr 2024 | 16 |
May 2024 | 16 |
Jun 2024 | 16 |
Jul 2024 | 16 |
Synthetic Biologics other data
Period | Buy | Sel |
---|---|---|
Dec 2022 | 100000 | 0 |
Jan 2023 | 50000 | 0 |
Feb 2023 | 50000 | 0 |
Jun 2023 | 40000 | 0 |
Patent |
---|
Application Filling date: 16 Jul 2020 Issue date: 18 Aug 2022 |
Application Filling date: 21 Apr 2022 Issue date: 4 Aug 2022 |
Application Filling date: 5 May 2020 Issue date: 14 Jul 2022 |
Application Filling date: 5 May 2020 Issue date: 30 Jun 2022 |
Application Filling date: 10 Jan 2022 Issue date: 28 Apr 2022 |
Application Filling date: 8 Dec 2021 Issue date: 31 Mar 2022 |
Application Filling date: 23 Nov 2021 Issue date: 24 Mar 2022 |
Grant Filling date: 4 Jun 2020 Issue date: 22 Feb 2022 |
Grant Filling date: 24 Jul 2020 Issue date: 1 Feb 2022 |
Application Filling date: 19 Aug 2021 Issue date: 6 Jan 2022 |
Quarter | Transcript |
---|---|
Q2 2022 11 Aug 2022 | Q2 2022 Earnings Call Transcript |
Q1 2022 16 May 2022 | Q1 2022 Earnings Call Transcript |
Q4 2021 16 Mar 2022 | Q4 2021 Earnings Call Transcript |
Q3 2021 3 Nov 2021 | Q3 2021 Earnings Call Transcript |
Insider | Compensation |
---|---|
Mr. Steven A. Shallcross CPA (1961) Chief Executive Officer, Chief Financial Officer, Treasurer, Corporation Sec. & Director | $941,990 |
-
What's the price of Synthetic Biologics stock today?
One share of Synthetic Biologics stock can currently be purchased for approximately $1.02.
-
When is Synthetic Biologics's next earnings date?
Unfortunately, Synthetic Biologics's (SYN) next earnings date is currently unknown.
-
Does Synthetic Biologics pay dividends?
No, Synthetic Biologics does not pay dividends.
-
How much money does Synthetic Biologics make?
Synthetic Biologics has a market capitalization of 16.16M. Synthetic Biologics made a loss 19.69M US dollars in net income (profit) last year or -$0.31 on an earnings per share basis.
-
What is Synthetic Biologics's stock symbol?
Synthetic Biologics, Inc. is traded on the AMEX under the ticker symbol "SYN".
-
What is Synthetic Biologics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Synthetic Biologics?
Shares of Synthetic Biologics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Synthetic Biologics's key executives?
Synthetic Biologics's management team includes the following people:
- Mr. Steven A. Shallcross CPA Chief Executive Officer, Chief Financial Officer, Treasurer, Corporation Sec. & Director(age: 64, pay: $941,990)
-
How many employees does Synthetic Biologics have?
As Jul 2024, Synthetic Biologics employs 16 workers.
-
When Synthetic Biologics went public?
Synthetic Biologics, Inc. is publicly traded company for more then 32 years since IPO on 12 Feb 1993.
-
What is Synthetic Biologics's official website?
The official website for Synthetic Biologics is syntheticbiologics.com.
-
Where are Synthetic Biologics's headquarters?
Synthetic Biologics is headquartered at 9605 Medical Center Dr Ste 270, Rockville, MARYLAND.
-
How can i contact Synthetic Biologics?
Synthetic Biologics's mailing address is 9605 Medical Center Dr Ste 270, Rockville, MARYLAND and company can be reached via phone at +1 734 332 7800.
Synthetic Biologics company profile:

Synthetic Biologics, Inc.
syntheticbiologics.comAMEX
16
Biotechnology
Healthcare
Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral Ăź-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Synthetic Biologics, Inc. is headquartered in Rockville, Maryland.
Rockville, MARYLAND 20850
CIK: 0000894158
ISIN: US87164U4094
CUSIP: 87164U409